Piper Sandler

Business

Piper Sandler Lifts Diamondback Energy Target to $218, Citing Permian Basin Strength Amid Volatile Oil Pricing

Analysts at Piper Sandler have increased their price target for Permian Basin-focused producer Diamondback Energy (FANG) to $218, maintaining an Overweight rating. The move comes as the firm anticipates solid Q4 results for gas-focused companies, while oil producers navigate a tougher pricing environment.

Business

Piper Sandler Trims Price Target for Expand Energy (EXE) Amid Shifting Natural Gas Landscape

Analysts at Piper Sandler have slightly lowered their price target for Expand Energy (EXE), the natural gas giant formed from a recent mega-merger, reflecting near-term pressures but maintaining a bullish long-term outlook for the sector.

Business

Piper Sandler Stays Bullish on AGNC Investment, Sees Opportunity in Narrowing MBS Spreads

Analyst firm Piper Sandler reiterates its Overweight rating on AGNC Investment Corp., highlighting a favorable shift in agency mortgage-backed securities spreads that could bolster the REIT's book value.

Business

Piper Sandler Bullish on Stryker, Sees 17% Upside Fueled by New Robotic Tech

Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.

Business

Century Therapeutics Gains Analyst Confidence with Extended Cash Runway and Key IND Submission on Horizon

Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.

Business

Edwards Lifesciences Gains Analyst Favor as Renewed Growth Cycle Takes Hold

Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.

Business

Medtronic's Growth Outlook Tempered by Survey on Renal Denervation Adoption

A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.

Business

Occidental Petroleum's Rocky Road: Analysts Remain Cautious Despite Recent Oil-Price Tailwinds

While rising crude prices have lifted Occidental Petroleum's stock recently, a mixed earnings performance and a predominantly 'Hold' rating from Wall Street signal lingering skepticism about its near-term trajectory.

Business

Guggenheim More Than Doubles Erasca Price Target to $12 on Clinical Progress and Pipeline Updates

Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.

Business

LifeSci Capital Boosts Price Target on Olema Pharmaceuticals, Citing Promising Breast Cancer Drug Pipeline

LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.

Business

AMD's AI Ambitions Fuel Stock Surge, Drawing Bullish Analyst Praise

Advanced Micro Devices (AMD) shares have soared over 115% in the past year, driven by its strategic positioning in the artificial intelligence sector. Recent analyst upgrades highlight optimism around its partnership with OpenAI and broader AI chip demand.

Business

Karman Holdings (KRMN) Soars on Analyst Optimism: A Defense Tech Darling in the Making?

Karman Holdings (NYSE: KRMN) is capturing Wall Street's attention as a series of bullish analyst calls, including a significant price target hike from KeyBanc, fuel its ascent. The stock's rally is tied to sustained momentum in the aerospace and defense sector, though some advise caution after its rapid gains.

Business

DigitalOcean Soars as 'Clawdbot' AI Assistant Drives Analyst Optimism and Price Target Hikes

Bank of America leads a wave of analyst upgrades for DigitalOcean, citing the viral success of its AI agent 'Clawdbot' and the company's strategic positioning in the burgeoning agentic AI market for developers.

Business

Webber Wentzel and Blake Cassels & Graydon Dominate 2025 Mining M&A Legal Advisory Ranks

New data reveals a two-horse race in mining sector legal advisory, with Webber Wentzel leading by total deal value and Blake Cassels & Graydon topping the charts by number of transactions in a year marked by megadeals.

Business

Latham & Watkins Tops 2025 TMT M&A Legal Rankings, Kirkland & Ellis in Close Pursuit

A new industry report reveals Latham & Watkins advised on a record $370bn in tech, media, and telecom deals last year, narrowly edging out rivals in a highly competitive legal advisory market.